SW033291-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESW033291Cat.No.:HY-16968CASNo.:459147-39-8分?式:C??H??N?OS?分?量:412.59作?靶點:15-PGDH作?通路:MetabolicEnzyme/Protease儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:33.33mg/mL(80.78mM;ultrasonicandwarmingandheatto70°C)Ethanol:25mg/mL(60.59mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.4237mL12.1186mL24.2371mL5mM0.4847mL2.4237mL4.8474mL10mM0.2424mL1.2119mL2.4237mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:2.5mg/mL(6.06mM);Suspendedsolution;Needultrasonic2.請依序添加每種溶劑：10%EtOH>>40%PEG300>>5%Tween-80>>45%salineSolubility:2.5mg/mL(6.06mM);Suspendedsolution;Needultrasonic3.請依序添加每種溶劑：10%EtOH>>90%(20%SBE-β-CDinsaline)Solubility:2.5mg/mL(6.06mM);Suspendedsolution;Needultrasonic4.請依序添加每種溶劑：10%EtOH>>90%cornoilSolubility:≥2.5mg/mL(6.06mM);ClearsolutionBIOLOGICALACTIVITY?物活性SW033291?種有效且?親和?的15-PGDH抑制劑，Ki為0.1nM。SW033291增加?髓和其他組織中前列腺素PGE2的?平。SW033291還可促進組織再?。IC50&TargetKi:0.1nM(15-PGDH)[1]體外研究TreatingcellswithSW033291decreasescellular15-PGDHenzymeactivityby85%.SW033291inhibitionof15-PGDHwasnon-competitiveversusPGE2overconcentrationsupto40μMPGE2.TreatmentofA549cellswithSW033291increasesPGE2levelsby3.5-foldat500nM,withanEC5050atapproximately75nM[1].體內(nèi)研究SW033291(10mg/kg;intraperitonealinjection;twicedaily;for3days;C57BL/6Jmice)treatmentforthreeconsecutivedaysshowssignificantbenefits,includingadoublingofperipheralneutrophilcounts,a65%increaseinmarrowSKLcells,anda71%increaseinmarrowSLAMcells[1].AnimalModel:C57BL/6Jmice[1]Dosage:10mg/kgAdministration:Intraperitonealinjection;twicedaily;for3days(for5doses)Result:Showedsignificantbenefits,includingadoublingofperipheralneutrophilcounts,a65%increaseinmarrowSKLcells,anda71%increaseinmarrowSLAMcells.戶使?本產(chǎn)品發(fā)表的科研?獻?StemCellResTher.2020Feb21;11(1):76.?JInvestDermatol.2021Sep6;S0022-202X(21)02171-0.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ZhangY,etal.TISSUEREGENERATION.Inhibitionoftheprostaglandin-degradingenzyme15-PGDHpotentiatestissueregeneration.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEScience.2015Jun12;348(6240):aaa2340.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedic